Generate Biomedicines, Inc. Common Stock Total Liabilities
Generate Biomedicines, Inc. Common Stock total liabilities. Based on the latest financial reports, Generate Biomedicines, Inc. Common Stock (GENB) has total liabilities worth $105.64 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Generate Biomedicines, Inc. Common Stock asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Generate Biomedicines, Inc. Common Stock (2024–2025)
Total liabilities of Generate Biomedicines, Inc. Common Stock from 2024 to 2025. This chart illustrates how Generate Biomedicines, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Generate Biomedicines, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Generate Biomedicines, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UIE PLC
CO:UIE
|
Denmark | Dkr121.46 Million |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥2.80 Billion |
|
Sinda Ltd.
NYSE:SIND
|
USA | $7.41 Million |
|
Gelsenwasser AG
F:WWG
|
Germany | €1.76 Billion |
|
Veris Residential Inc
NYSE:VRE
|
USA | $1.51 Billion |
|
Blackstone Mortgage Trust Inc
NYSE:BXMT
|
USA | $16.21 Billion |
|
CHN Energy Changyuan Electric Power Co Ltd
SHE:000966
|
China | CN¥26.75 Billion |
|
Argan SA
PA:ARG
|
France | €2.37 Billion |
Liability Composition Analysis (2024–2025)
This chart breaks down Generate Biomedicines, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see GENB total assets.
Liquidity & Leverage Metrics
Generate Biomedicines, Inc. Common Stock Total Liabilities Ratios Explained
Generate Biomedicines, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Generate Biomedicines, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Generate Biomedicines, Inc. Common Stock (2024–2025)
The table below shows the annual total liabilities of Generate Biomedicines, Inc. Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $953.38 Million | +0.00% |
| 2024-12-31 | $953.35 Million | -- |
About Generate Biomedicines, Inc. Common Stock
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is … Read more